JPS6337625B2 - - Google Patents
Info
- Publication number
- JPS6337625B2 JPS6337625B2 JP56084789A JP8478981A JPS6337625B2 JP S6337625 B2 JPS6337625 B2 JP S6337625B2 JP 56084789 A JP56084789 A JP 56084789A JP 8478981 A JP8478981 A JP 8478981A JP S6337625 B2 JPS6337625 B2 JP S6337625B2
- Authority
- JP
- Japan
- Prior art keywords
- medium
- present
- organic acid
- dme
- dulbecco
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 10
- 150000007524 organic acids Chemical class 0.000 claims description 7
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 6
- 235000013878 L-cysteine Nutrition 0.000 claims description 5
- 239000004201 L-cysteine Substances 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- 239000001384 succinic acid Substances 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229940074404 sodium succinate Drugs 0.000 claims description 2
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 1
- 235000019393 L-cystine Nutrition 0.000 claims 1
- 239000004158 L-cystine Substances 0.000 claims 1
- 229960003067 cystine Drugs 0.000 claims 1
- 239000002609 medium Substances 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229960002433 cysteine Drugs 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 description 1
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- QIJRTFXNRTXDIP-JIZZDEOASA-N L-cysteine hydrochloride hydrate Chemical compound O.Cl.SC[C@H](N)C(O)=O QIJRTFXNRTXDIP-JIZZDEOASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- ASIYFCYUCMQNGK-JZGIKJSDSA-L disodium L-tyrosinate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CC1=CC=C([O-])C=C1 ASIYFCYUCMQNGK-JZGIKJSDSA-L 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- -1 iron ions Chemical class 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- FCHXJFJNDJXENQ-UHFFFAOYSA-N pyridoxal hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(C=O)=C1O FCHXJFJNDJXENQ-UHFFFAOYSA-N 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- ZBTUYCUNQBRXOR-UHFFFAOYSA-L sodium succinate hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-]C(=O)CCC([O-])=O ZBTUYCUNQBRXOR-UHFFFAOYSA-L 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical class Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
【発明の詳細な説明】
本発明は高圧滅菌可能な新規なダルベツコ変法
イーグル培地(以下、DME培地と称する)に関
する。
DME培地はアール・ダルベツコ(R.
Dulbecco)らによつて開発された培地であり、
公知のイーグルMEM中のアミノ酸濃度を約2倍
及びビタミン濃度を約4倍にすることにより培養
細胞の増殖に必要な栄養源を豊富にし、これに更
にグリシン、セリン、ピルビン酸及び鉄イオンを
添加した改良型のイーグルMEMであり、種々の
細胞の初代培養や単細胞培養を行う目的で広く使
用されている。特にDME培地は、細胞にウイル
スを感染させたのち血清を含まない培地に変えて
も細胞を長く維持できる培地として広く使用され
ている。
このDME培地は当初は液体培地であつたが、
その後製法の改良がなされ、現在は長期間保存可
能な粉末培地として提供されている。
しかしながら、当該粉末培地は、その使用に先
立つて溶解され滅菌処理されなければならない。
培地の滅菌法として、現在最も効果的かつ操作の
簡単な方法は高圧滅菌法である。しかし、従来の
DME培地は、これを高圧滅菌処理に付すと、細
胞増殖に対する支持力が著しく低下するので、細
菌過器による滅菌を余儀無くされていた。しか
しながら、細菌過器による滅菌法は、細菌効果
が不充分であると共に多くの手数と時間を要する
欠点があり、従来から、高圧滅菌可能なDME培
地の開発が所望されていた。
そこで、本発明者は斯る問題点を解決せんと鋭
意研究を行つた結果、当該培地の処方中の熱に対
して不安定なものを除去乃至は他のもので代替
し、かつ有機酸緩衝剤を含有せしめることによ
り、高圧滅菌処理を行つても細胞増殖に対する支
持力の低下のみられないDME培地が得られるこ
とを見出し、本発明を完成した。
すなわち、本発明はDME培地の処方中からL
―グルタミン及びL―シスチンを除去し、代りに
L―システイン並びに有機酸とその塩との組合せ
からなる有機酸緩衝剤を含有せしせた高圧滅菌型
DME培地を提供するものである。
本発明で使用される有機酸緩衝剤としては、PH
が4.25になるもの、例えば酢酸と酢酸ナトリウ
ム、コハク酸とコハク酸ナトリウム等が好まし
い。
本発明の高圧滅菌型DME培地の代表的処方
(以下、本発明培地粉末と称する)は次のとおり
である。
塩化ナトリウム 6400.0(mg)
塩化カリウム 400.0
塩化カルシウム 200.0
硫酸マグネシウム 97.7
リン酸二水素ナトリウム(無水) 108.0
硝酸第二鉄(九水塩) 0.1
ブドウ糖 1000.0
ピルビン酸ナトリウム 110.0
コハク酸 106.0
コハク酸ナトリウム(六水塩) 27.0
L―アルギニン塩酸塩 84.0
L―システイン塩酸塩(一水塩) 70.3
グリシン 30.0
L―ヒスチジン塩酸塩(一水塩) 42.0
L―イソロイシン 104.8
L―ロイシン 104.8
L―リジン塩酸塩 146.2
L―メチオニン 30.0
L―フエニルアラニン 66.0
L―セリン 42.0
L―スレオニン 95.2
L―トリプトフアン 16.0
L―チロシン二ナトリウム 89.5
L―バリン 93.6
重酒石酸コリン 7.2
葉酸 4.0
ニコチン酸アミド 4.0
パントテン酸カルシウム 4.0
ピリドキサール塩酸塩 4.0
リボフラビン 0.4
チアミン塩酸塩 4.0
i―イノシトール 7.2
フエノールレツド 5.0
全量 9503.0
本発明高圧滅菌型DME培地は上記成分を常法
に従つて混和することにより製造される。尚
DME培地には一般に細胞の増殖を図るために10
%前後の血清を添加して使用するが、血清の添加
量が少ない場合、L―シスチンの代りにL―シス
テインを含有させた本発明培地の高圧滅菌に対す
る有利性は特に顕著である。
次に実施例を挙げて説明する。
実施例 1
DME培地粉末(市販品)10.0gを1の蒸
留水に溶解し、炭酸水素ナトリウム1.2gを加
えて完全に溶解させた。これをポアサイズ0.2μ
のフイルターで過滅菌して、DME培地(以
下、従来培地と称する)を得た。
本発明培地粉末9.5gを1の蒸留水に溶解
し、121℃で15分間高圧滅菌し、これに冷後、
溶解、過滅菌したL―グルタミン0.584g及
び炭酸水素ナトリウム1.2gを加えて培地(本
発明培地と称する)を得た。
本発明培地粉末の処方中のL―システイン塩
酸塩・一水塩(70.3mg)の代りにL―シスチン
二塩酸塩(62.6mg)を加えたものを、と同様
に操作して培地(比較培地と称する)を得た。
上で得た3つの培地に新生子牛の血清を濃度が
2%になるように加え、次の条件下でヒト子宮ガ
ン細胞由来の細胞株Hela―S3の培養を行い、そ
の増殖を調べた。
φ6cmプラスチツクシヤーレ(培地量5ml)植
込細胞数5×104セル/Dish37℃、5%炭酸ガス。
その結果は第1図に示すとおりである。
実施例 2
実施例1の〜と同様にして調整した各培地
にヒト子宮ガン細胞由来の細胞株Hela―S3の培
養を行い、そのコロニー形成率を調べた。ただし
血清濃度は5%及び2%の場合について調べた。
各測定とも5枚のシヤーレにより調べた結果を次
表に示す。
【表】DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel Dulbecco's modified Eagle medium (hereinafter referred to as DME medium) that can be sterilized under high pressure. DME medium was prepared by Earl Dulbetsko (R.
This is a medium developed by Dulbecco et al.
By doubling the amino acid concentration and quadrupling the vitamin concentration of the known Eagle MEM, we enriched the nutrients necessary for the growth of cultured cells, and further added glycine, serine, pyruvate, and iron ions. This is an improved type of Eagle MEM, which is widely used for primary culture and single cell culture of various cells. In particular, DME medium is widely used as a medium that can maintain cells for a long time even if cells are infected with a virus and then changed to a serum-free medium. This DME medium was initially a liquid medium, but
The manufacturing method has since been improved, and it is now available as a powdered medium that can be stored for a long period of time. However, the powdered medium must be dissolved and sterilized prior to its use.
Currently, the most effective and easy-to-operate method for sterilizing culture media is high-pressure sterilization. However, traditional
When a DME medium is subjected to high-pressure sterilization, its supporting capacity for cell growth is significantly reduced, so sterilization using a bacterial strainer has been unavoidable. However, the sterilization method using a bacterial strainer has the disadvantage that it has insufficient bactericidal effects and requires a lot of labor and time, and there has been a desire for the development of a DME medium that can be sterilized under high pressure. Therefore, the inventor of the present invention conducted intensive research to solve these problems, and as a result, removed or replaced the heat-labile substances in the formulation of the medium, and added an organic acid buffer. The present invention was completed based on the discovery that a DME medium that does not lose its supporting capacity for cell growth even after high-pressure sterilization can be obtained by containing the agent. That is, the present invention provides L from the formulation of DME medium.
- High-pressure sterilization type that removes glutamine and L-cysteine and instead contains L-cysteine and an organic acid buffer consisting of a combination of an organic acid and its salt.
It provides a DME medium. The organic acid buffer used in the present invention includes PH
is preferably 4.25, such as acetic acid and sodium acetate, succinic acid and sodium succinate, etc. A typical formulation of the autoclaved DME medium of the present invention (hereinafter referred to as the medium powder of the present invention) is as follows. Sodium chloride 6400.0 (mg) Potassium chloride 400.0 Calcium chloride 200.0 Magnesium sulfate 97.7 Sodium dihydrogen phosphate (anhydrous) 108.0 Ferric nitrate (nonahydrate) 0.1 Glucose 1000.0 Sodium pyruvate 110.0 Succinic acid 106.0 Sodium succinate (hexahydrate) ) 27.0 L-arginine hydrochloride 84.0 L-cysteine hydrochloride (monohydrate) 70.3 Glycine 30.0 L-histidine hydrochloride (monohydrate) 42.0 L-isoleucine 104.8 L-leucine 104.8 L-lysine hydrochloride 146.2 L-methionine 30.0 L-phenylalanine 66.0 L-serine 42.0 L-threonine 95.2 L-tryptophan 16.0 L-tyrosine disodium 89.5 L-valine 93.6 Choline bitartrate 7.2 Folic acid 4.0 Nicotinamide 4.0 Calcium pantothenate 4.0 Pyridoxal hydrochloride 4.0 Riboflavin 0 .4 Thiamin hydrochloride Salt 4.0 i-inositol 7.2 Phenol red 5.0 Total amount 9503.0 The autoclaved DME medium of the present invention is produced by mixing the above components in a conventional manner. still
DME medium generally contains 10
When the amount of serum added is small, the advantage of the medium of the present invention containing L-cysteine instead of L-cysteine in autoclaving is particularly remarkable. Next, an example will be given and explained. Example 1 10.0 g of DME medium powder (commercially available) was dissolved in 1 distilled water, and 1.2 g of sodium bicarbonate was added to completely dissolve it. This has a pore size of 0.2μ.
The DME medium (hereinafter referred to as conventional medium) was obtained by over-sterilizing with a filter. Dissolve 9.5 g of the present invention medium powder in 1 distilled water, autoclave at 121°C for 15 minutes, and after cooling,
A medium (referred to as the medium of the present invention) was obtained by adding 0.584 g of dissolved and oversterilized L-glutamine and 1.2 g of sodium bicarbonate. A medium (comparison medium ) was obtained. Newborn calf serum was added to the three media obtained above to a concentration of 2%, and the cell line Hela-S3 derived from human uterine cancer cells was cultured under the following conditions, and its proliferation was examined. . φ6cm plastic jar (medium volume: 5ml), number of implanted cells: 5 x 104 cells/dish, 37°C, 5% carbon dioxide gas. The results are shown in FIG. Example 2 Cell line Hela-S3 derived from human uterine cancer cells was cultured in each culture medium prepared in the same manner as in Example 1 to examine the colony formation rate. However, the serum concentration was investigated at 5% and 2%.
The following table shows the results of each measurement using five sheets of shear glass. 【table】
第1図は高圧滅菌した本発明培地に血清2%を
添加したものにおけるHeLa―S3株の増殖状態を
示す。
FIG. 1 shows the growth state of HeLa-S3 strain in an autoclaved medium of the present invention to which 2% serum was added.
Claims (1)
―グルタミン及びL―シスチンを除去し、代りに
L―システイン並びに有機酸とその塩との組合せ
からなる有機酸緩衝剤を含有せしめたことを特徴
とする高圧滅菌型ダルベツコ変法イーグル培地。 2 有機酸緩衝剤がコハク酸とコハク酸ナトリウ
ムとの組合せである特許請求の範囲第1項記載の
高圧滅菌型ダルベツコ変法イーグル培地。[Claims] 1 L from the formulation of Dulbecco's modified Eagle's medium
- An autoclaved Dulbecco's modified Eagle medium characterized in that glutamine and L-cystine have been removed and, instead, an organic acid buffer consisting of L-cysteine and a combination of an organic acid and its salt is contained. 2. The autoclaved Dulbecco's modified Eagle medium according to claim 1, wherein the organic acid buffer is a combination of succinic acid and sodium succinate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56084789A JPS57202288A (en) | 1981-06-02 | 1981-06-02 | Dulbecco modified eagle medium of high-pressure sterilization type |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56084789A JPS57202288A (en) | 1981-06-02 | 1981-06-02 | Dulbecco modified eagle medium of high-pressure sterilization type |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS57202288A JPS57202288A (en) | 1982-12-11 |
JPS6337625B2 true JPS6337625B2 (en) | 1988-07-26 |
Family
ID=13840460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP56084789A Granted JPS57202288A (en) | 1981-06-02 | 1981-06-02 | Dulbecco modified eagle medium of high-pressure sterilization type |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS57202288A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01303225A (en) * | 1988-05-28 | 1989-12-07 | Daifuku Co Ltd | Vessel supplying device on article classifying equipment |
-
1981
- 1981-06-02 JP JP56084789A patent/JPS57202288A/en active Granted
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01303225A (en) * | 1988-05-28 | 1989-12-07 | Daifuku Co Ltd | Vessel supplying device on article classifying equipment |
Also Published As
Publication number | Publication date |
---|---|
JPS57202288A (en) | 1982-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Neuman et al. | Dual requirement of Walker carcinosarcoma 256 in vitro for asparagine and glutamine | |
Roberts et al. | Further studies of glutamic acid decarboxylase in brain | |
Rueckert et al. | Studies on unbalanced growth in tissue culture: I. Induction and consequences of thymidine deficiency | |
CN108251353B (en) | Human embryo in-vitro culture solution and culture system | |
CN104911143B (en) | A kind of no albumen, serum free medium without hydrolysate and preparation method thereof | |
CN109337862B (en) | Sperm washing solution and preparation method and application thereof | |
CN108251355A (en) | Single step embryo medium | |
Swim et al. | The role of carbon dioxide as an essential nutrient for six permanent strains of fibroblasts | |
CN105454220A (en) | Placenta preservation method, placenta preservation solution and preparation method thereof | |
Moser | Modern approaches to the study of mammalian cells in culture | |
US3936355A (en) | Microorganism growth media and the stabilization thereof | |
JPS6337625B2 (en) | ||
CN115433705B (en) | Chemically defined medium for culturing BHK21 cells, additive and application thereof | |
Kay | The inhibition of bacteriophage multiplication by proflavine and its reversal by certain polyamines | |
CN110669724A (en) | Saccharum embryo culture solution and preparation method thereof | |
BE1022290B1 (en) | FERMENTATION PROCESS | |
Hanss et al. | Studies of culture media for the growth of human tumor cells | |
JPS60114192A (en) | Culture method and medium of ant poison gland cell | |
GB1192340A (en) | Improvements in or relating to Tissue Culture media | |
CN114540274A (en) | Serum-free medium, preparation method thereof and method for culturing 2BS (2 BS) cells by using serum-free medium | |
JPH06189781A (en) | Stabilization of bioactive protein in culture solution | |
SU1654338A1 (en) | Nutrient medium for restoration after cryoconservation of hybridous mammalian cells, mus musculus l - producers antiinfluenza monoclonal antibodies | |
CN117210401B (en) | Preparation and culture medium for promoting mesenchymal stem cell adherent growth and preparation method thereof | |
CN116790483A (en) | CHO cell serum-free medium and application thereof | |
Garnett | The effect of arginine deprivation on the cytopathogenic effect and replication of human cytomegalovirus |